Clinical trials: Old Adults
Infections, Meningococcal
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination
The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10 years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ or Mencevax™ ACWY, and the…
- Trial name
- NCT01962207
- Testing
- Meningococcal vaccine GSK134612
- Where
- 9 sites in Finland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide…
- Trial name
- NCT00464672
- Testing
- Influenza virus vaccine, Comparator influenza vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Novartis
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Persistent Asthma
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a…
- Trial name
- NCT02040779
- Testing
- Beclomethasone dipropionate breath-actuated inhaler, albuterol/salbutamol
- Where
- 47 sites in United States
- Volunteers
- 273 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hepatitis B
Hepatitis B Challenge Dose in Adults (V232-059-10)
The purpose of this trial is to describe the Seroprotection Rate (SPR) at least 2 years following completion of a primary series with a hepatitis B vaccine (Base Study V232-059, NCT00440531) and 1 month following a challenge dose…
- Trial name
- NCT01251276
- Testing
- Modified Process Hepatitis B Vaccine
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Falls (Accidents) in Old Age
Evaluating Technology-Based Fall Prevention Interventions
Approximately one in three older adults fall annually and it is the primary cause of traumatic injury in older adults. While exercise and balance programs have been shown to be effective in reducing fall risk, maintaining…
- Trial name
- FaCT2 (NCT03190460)
- Testing
- Cognitive Training, Technology-based Education
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Washington
Temple Hollowing
A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old
The objectives of this study are to evaluate the safety and effectiveness of Juvederm® Voluma® XC injectable gel in adult participants seeking correction of temple hollowing
- Trial name
- NCT04414397
- Testing
- JUVÉDERM® VOLUMA® XC, No-treatment control
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 205 people
- Sponsor
- Allergan
ADHD
Adult Normative Performance of the Quotient ADHD System
This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System…
- Trial name
- ADHD (NCT01308450)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- BioBehavioral Diagnostics Company
Leukemia
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00814164
- Testing
- clofarabine, daunorubicin hydrochloride, cytogenetic analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Epilepsy, Partial
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152503
- Testing
- Seletracetam (UCB44212)
- Where
- 17 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- UCB Pharma SA
Epilepsy
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
- Trial name
- NCT00490035
- Testing
- Brivaracetam
- Where
- 76 sites in Belgium, Finland and 10 more
- Volunteers
- 399 people
- Sponsor
- UCB Pharma SA
Infections, Meningococcal
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
The purpose of this study is to evaluate the long-term antibody persistence from 6, 7, 8, 9 to 10 years post-administration of MenACWY-TT conjugate vaccine as compared to Mencevax ACWY when given to healthy subjects 11 to 55…
- Trial name
- NCT01934140
- Testing
- Meningococcal vaccine GSK134612
- Where
- 2 sites in Philippines
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- Pfizer
Avian Influenza, Influenza Immunisation
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females, 18-64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017…
- Trial name
- NCT03682120
- Testing
- A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
- Where
- 7 sites in United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS).
- Trial name
- NCT02873286
- Testing
- MVA-BN-RSV
- Where
- 12 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00699283
- Testing
- Brivaracetam
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- UCB Pharma
Plasmodium Falciparum
Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
The main goal of this study is to assess the efficacy of RTS,S/AS01E, a candidate vaccine against malaria caused by Plasmodium falciparum (P. falciparum), in adults positive for P.
- Trial name
- NCT04661579
- Testing
- Malaria Vaccine RTS,S/AS01E, Abhayrab rabies vaccine, Dihydroartemisinin-piperaquine (DHA/Pip)
- Where
- Kenya
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- PATH
Metabolic Syndrome, Normal Cognition
Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older
Background: In Alzheimer s disease (AD) the brain cannot use glucose as a fuel. The brain can use ketones as a fuel instead of glucose. Researchers want to test a supplement, Ketone Ester (KE).
- Trial name
- NCT04421014
- Testing
- Ketone Ester drink
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Institute on Aging (NIA)